bluebird bio Inc (NASDAQ:BLUE) price target lowered to $163.00 by Maxim Group

ME Staff
-
0

Analyst Ratings For bluebird bio Inc (NASDAQ:BLUE)

Today, Maxim Group lowered its price target on bluebird bio Inc (NASDAQ:BLUE) to $163.00 per share.

There are 14 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on bluebird bio Inc (NASDAQ:BLUE) is Buy with a consensus target price of $212.90 per share, a potential 38.29% upside.

Some recent analyst ratings include

  • 7/12/2018-Gabelli initiated coverage with a Buy rating.
  • 6/19/2018-Evercore ISI Upgrade from a “In-Line ” rating to a ” Outperform” rating.
  • 6/4/2018-Cowen Reiterated Rating of Buy.
  • 5/7/2018-Sanford C. Bernstein Reiterated Rating of Market Perform.


  • On 7/11/2018 David Davidson, Insider, sold 3,000 with an average share price of $180.15 per share and the total transaction amounting to $540,450.00.
  • On 7/9/2018 Jason Cole, Insider, sold 5,126 with an average share price of $170.25 per share and the total transaction amounting to $872,701.50.
  • On 7/2/2018 David Davidson, Insider, sold 10,000 with an average share price of $153.96 per share and the total transaction amounting to $1,539,600.00.
  • On 6/18/2018 Philip D Gregory, Insider, sold 3,901 with an average share price of $178.41 per share and the total transaction amounting to $695,977.41.
  • On 6/14/2018 Mark Vachon, Director, sold 1,000 with an average share price of $189.99 per share and the total transaction amounting to $189,990.00.
  • On 6/4/2018 David Davidson, Insider, sold 13,000 with an average share price of $187.84 per share and the total transaction amounting to $2,441,920.00.
  • On 6/4/2018 Mark Vachon, Director, sold 6,000 with an average share price of $188.22 per share and the total transaction amounting to $1,129,320.00.

About bluebird bio Inc (NASDAQ:BLUE)
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Recent Trading Activity for bluebird bio Inc (NASDAQ:BLUE)
Shares of bluebird bio Inc closed the previous trading session at 153,50 −9,00 5,54 % with 153.1 shares trading hands.